Elevance Health (ELV) Q4 Earnings and Revenues Beat Estimates
Elevance Health (ELV) came out with quarterly earnings of $3.84 per share, beating the Zacks Consensus Estimate of $3.80 per share. This compares to earnings of $5.62 per share a year ago.
Elevance Health Q4 2024 Earnings: Managed Care Continues To Impress
Despite a 29% drop in Elevance Health's stock, I maintain a strong buy rating due to a DCF price target of $549.60, indicating 43% upside. ELV's shift towards managed care, with strong industry tailwinds, supports sustainable margin expansion and revenue growth, making it a compelling investment. Regulatory risks around Pharmacy Benefit Management are mitigated by CarelonRx's diversified revenue streams and a healthy margin of safety in my modeling.
Elevance Stock Gains After Strong Quarter. A Dividend Hike Is Another Positive.
The health insurer's fourth-quarter adjusted earnings top analysts' estimates.
Elevance Health earnings boost health-insurance stocks after upbeat outlook
UnitedHealth, Humana and Centene all rally premarket
Elevance beats quarterly profit estimates on lower-than-expected medical costs
Elevance beat Wall Street estimates for quarterly profit on Thursday, as the health insurer spent less than expected on the medical costs of its members.
Elevance Health Q4 Countdown: Smart Move to Buy or Stick With Hold?
ELV's fourth-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Unveiling Elevance Health (ELV) Q4 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Elevance Health (ELV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Elevance Health Is An Undervalued Healthcare Juggernaut
Elevance Health is a strong buy despite a 30% stock decline, due to its solid fundamentals and market position in the health insurance industry. The company benefits from secular trends like an aging population and increased life expectancy, driving long-term demand for healthcare services. Key risks include rising healthcare costs and a shrinking Medicaid member base, impacting margins and free cash flow.
Elevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?
ELV is reallocating resources to more profitable areas and making prudent acquisitions.
Elevance Health: A Quality Underpriced Stock Returning To Health
Elevance Health has shown robust financial performance, with a 9.1% revenue CAGR and 13.7% EPS growth over the past decade. Despite recent share price weakness, ELV's long-term fundamentals remain strong, presenting an investment opportunity. ELV's valuation is attractive, with a forward PE of 11.2x, lower than its 10-year average, and potential upside driven by AI integration.
Elevance Health Stock Falls As Anthem Faces Backlash Over Anesthesia Policy, Announces Reversal
When Anthem Blue Cross Blue Shield said it will no longer pay for anesthesia care if the surgery or procedure exceeds an arbitrary time limit, parent company Elevance Health Inc ELV faced backlash and reneged on the policy change.
Elevance Health Declines 20% in 3 Months: Time to Sell the Stock?
ELV encounters headwinds such as higher benefit costs, an increased debt level and member attrition in the Medicaid business, which raise concerns among investors.
